日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Cross-Sectional analysis of demographic and clinical characteristics of patients in the United States using icosapent ethyl

对美国使用二十碳五烯酸乙酯患者的人口统计学和临床特征进行横断面分析

Toth, Peter P; Nelson, John R; Soran, Handrean; Ganda, Om P; Wong, Nathan D; Hannachi, Hakima; Abrahamson, David; Hartman, Josh; Luciano, Sierra; Philip, Sephy

Cost-Effectiveness of Icosapent Ethyl in REDUCE-IT USA: Results From Patients Randomized in the United States

REDUCE-IT USA 研究中二十碳五烯酸乙酯的成本效益:来自美国随机分组患者的结果

Weintraub, William S; Bhatt, Deepak L; Zhang, Zugui; Dolman, Sarahfaye; Boden, William E; Bress, Adam P; Bellows, Brandon K; Derington, Catherine G; Philip, Sephy; Steg, Gabriel; Miller, Michael; Brinton, Eliot A; Jacobson, Terry A; Tardif, Jean-Claude; Ballantyne, Christie M; Kolm, Paul

Re: 'Cardiovascular outcomes of ethyl eicosapentaenoic acid in diabetes mellitus: a meta-analysis'

回复:'乙基二十碳五烯酸对糖尿病患者心血管结局的影响:一项荟萃分析'

Philip, Sephy

The potential population health impact of treating REDUCE-IT eligible US adults with Icosapent Ethyl

使用二十碳五烯酸乙酯治疗符合 REDUCE-IT 条件的美国成年人可能对人群健康产生的影响

Derington, Catherine G; Bress, Adam P; Herrick, Jennifer S; Fan, Wenjun; Wong, Nathan D; Andrade, Katherine E; Johnson, Jonathan; Philip, Sephy; Abrahamson, David; Jiao, Lixia; Bhatt, Deepak L; Weintraub, William S

Increased residual cardiovascular risk in U.S. veterans with moderately-elevated baseline triglycerides and well-controlled LDL-C levels on statins

美国退伍军人即使基线甘油三酯水平中度升高,且服用他汀类药物后低密度脂蛋白胆固醇(LDL-C)水平控制良好,其心血管残余风险仍然增加。

Leatherman, Sarah; Ferguson, Ryan; Hau, Cynthia; Harrington, Kelly; Granowitz, Craig; Philip, Sephy; Toth, Peter Paul; Bhatt, Deepak; Boden, William

Triglyceride Levels and Residual Risk of Atherosclerotic Cardiovascular Disease Events and Death in Adults Receiving Statin Therapy for Primary or Secondary Prevention: Insights From the KP REACH Study

接受他汀类药物治疗进行一级或二级预防的成年人中,甘油三酯水平与动脉粥样硬化性心血管疾病事件和死亡的残余风险:来自KP REACH研究的启示

Ambrosy, Andrew P; Yang, Jingrong; Sung, Sue Hee; Allen, Amanda R; Fitzpatrick, Jesse K; Rana, Jamal S; Wagner, Jeffrey; Philip, Sephy; Abrahamson, David; Granowitz, Craig; Go, Alan S

Rationale and design of the pragmatic randomized trial of icosapent ethyl for high cardiovascular risk adults (MITIGATE)

针对高心血管风险成年人的二十碳五烯酸乙酯实用性随机试验(MITIGATE)的原理和设计

Ambrosy, Andrew P; Malik, Umar I; Thomas, Rachel C; Parikh, Rishi V; Tan, Thida C; Goh, Choon H; Selby, Van N; Solomon, Matthew D; Avula, Harshith R; Fitzpatrick, Jesse K; Skarbinski, Jacek; Philip, Sephy; Granowitz, Craig; Bhatt, Deepak L; Go, Alan S

The association between triglycerides and incident cardiovascular disease: What is "optimal"?

甘油三酯与心血管疾病发病率之间的关联:什么是“最佳”水平?

Aberra, Tsion; Peterson, Eric D; Pagidipati, Neha J; Mulder, Hillary; Wojdyla, Daniel M; Philip, Sephy; Granowitz, Craig; Navar, Ann Marie

Prevalence of US Adults with Triglycerides ≥ 150 mg/dl: NHANES 2007-2014

美国成年人甘油三酯≥150 mg/dl的患病率:NHANES 2007-2014

Fan, Wenjun; Philip, Sephy; Granowitz, Craig; Toth, Peter P; Wong, Nathan D

Mineral oil: safety and use as placebo in REDUCE-IT and other clinical studies

矿物油:在 REDUCE-IT 和其他临床研究中作为安慰剂的安全性和用途

Olshansky, Brian; Chung, Mina K; Budoff, Matthew J; Philip, Sephy; Jiao, Lixia; Doyle, Ralph T Jr; Copland, Christina; Giaquinto, Alex; Juliano, Rebecca A; Bhatt, Deepak L